INVESTIGATIVE REPORT

Role of Small Intestinal Bacterial Overgrowth and *Helicobacter pylori* Infection in Chronic Spontaneous Urticaria: A Prospective Analysis

Anna CAMPANATI 1, Rosaria GESUITA 2, Melanie GIANNONI 1, Francesca PIRACCINI 2, Lucia SANDRONI 2, Emanuela MARTINA 1, Luca CONOCCHIARI 1, Emanuele BENDIA 1, Antonio DI SARIO 3 and Annamaria OFFIDANI 1

1Dermatology Clinic, Department of Clinical and Molecular Medicine; 2Centre of Epidemiology and Biostatistics, Department of Clinical Medicine and Applied Biotechnologies; and 3Gastroenterology Clinic, Department of Clinical and Molecular Medicine, Polytechnic Marche University, Ancona, Italy

Urticaria is a heterogeneous group of diseases (1, 2). According to concensus guidelines, chronic spontaneous urticaria (CSU) (lasting more than 6 weeks) is characterized by wheals arising spontaneously without external physical stimuli (1).

Published data suggest a possible association between CSU and infections of the nasopharynx and gastrointestinal tract, focusing on *Helicobacter pylori* (HP) (1–4). However, the prevalence of HP infection in patients with CSU is uncertain, and published studies on the association between these two conditions have several methodological limitations.

Another pathological condition of the gastrointestinal tract is small intestinal bacterial overgrowth (SIBO), a condition in which excessive levels of bacteria, mainly the colonic-type species are present in the small intestine (5). An association between SIBO and rosacea has been demonstrated (6). No data have been published about the relationship between SIBO and CSU.

This aim of this study is to:
- evaluate the prevalence of SIBO and HP infection in a group of patients with CSU;
- establish whether SIBO or HP infection are associated with the severity of clinical disease;
- determine whether the eradication of SIBO or HP infection is associated with significant clinical improvement in CSU.

MATERIALS AND METHODS

Study sample

This prospective study was conducted on 51 patients hospitalized for CSU at the Dermatology Clinic, Ospedali Riuniti di Ancona, Ancona, Italy, between September 2009 and November 2010. The study was approved by the local ethics committee and conducted in conformity with the Declaration of Helsinki.

No patient was taking non-steroidal anti-inflammatory drugs, angiotensin-converting enzymes inhibitors, hormones, laxatives, ear and eye drops, or had a previous malignancy or autoimmune disease. All patients were free from any CSU-specific systemic therapy during the study.

Laboratory analyses

All patients underwent routine blood tests (complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), liver, thyroid and kidney function), thyroid function (T3, T4, TSH), faecal parasites, anti-streptolysin positive titre (AST), and paper radioimmunosorbent test (PRIST), for determining total serum immunoglobulin E levels (7).

An identifiable antigenic cause was ruled out since the following in vivo tests gave negative results:
- autologous serum skin test (ASST), which is the best in vivo clinical test for detection of *in vitro* basophil histamine-releasing activity, with a sensitivity of 65–71% and specificity of 78–81% (8).
- skin prick test for common food and inhalant allergens (9).

Physical urticaria was excluded in all patients.
Urea breath test and glucose breath test

All patients underwent the urea breath test (UBT) for HP infection, and the glucose breath test (GBT) for SIBO.

The UBT was performed as described by Savarino et al. (10). The reported sensitivity and specificity for the UBT are 81–100% and 80–98%, respectively (11). A positive test was defined as when the relative amount of 13CO\textsubscript{2} increased > 4.0 δ 13CO\textsubscript{2}/ml.

The GBT was performed according to the indications of Gasbarrini et al. (12). The GBT has a sensitivity of 62.5% and a specificity of 82% (13). The test was positive for SIBO in the presence of H\textsubscript{2}/CH\textsubscript{4} production > 12 ppm compared with basal values.

All patients underwent the UBT and GBT at baseline, SIBO- and HP-positive patients received specific eradication treatment for one week, and 4 weeks later (T5) they repeated the test to evaluate the efficacy of eradication treatment.

Clinical evaluation of disease activity

Severity of symptoms and their impact on patients’ quality of life (QoL) were evaluated by the Urticaria Activity Score (UAS) and the Dermatology Life Quality Index (DLQI).

The UAS is a simple test to evaluate patient’s skin symptoms (14, 15): all patients were asked to complete a questionnaire daily to evaluate both the number of hives (mild urticaria: < 20 wheals/24 h; moderate urticaria: 20–50 wheals/24 h; intense urticaria: > 50 wheals in 24 h or large confluent areas of wheals), and the intensity of itching (mild: present but not annoying, moderate: troublesome without interfering with normal activity or sleep; intense: severe pruritus interfering with normal daily activity or sleep). The daily severity score ranges from 0 to 6, thus the final weekly UAS score ranges from 0 to 42 (1). This test allows the evaluation of CSU symptoms in a week.

The DLQI is a simple questionnaire consisting of 10 questions, used to evaluate the impact of skin diseases on QoL. The final score ranges from 0 to 30: the higher the score, the worse the QoL (16–18). The test was completed by patients both at baseline and 4 weeks after the eradication therapy.

Administered treatments for HP infection and SIBO

Patients with HP infection were treated with a combined antibiotic therapy, according to the American College of Gastroenterology Guidelines (19). Patient with SIBO were treated with rifamixin 1,200 mg/day for one week, as suggested by Bures et al. (20).

Statistical analyses

Quantitative variables were not normally distributed, therefore non-parametric tests were used.

The patients were analysed according to the presence of HP or SIBO infections and divided into 3 groups: patients negative for both HP and SIBO, patients positive for HP, and patients positive for SIBO. Categorical variables were expressed as absolute and percentage frequencies. Comparisons between groups were analysed with the Fisher’s exact test.

DLQI and UAS scores were measured at baseline and 4 weeks after the eradication treatment. The percentage variation for each score was calculated as follows: (values after−values before)/values before. DLQI and UAS at baseline and after eradication and their percentage variations were represented graphically using boxplots. Comparisons between groups were evaluated with the Kruskal-Wallis test.

The prevalences of HP and SIBO were estimated with a 95% confidence interval (95% CI) using a binomial distribution.

RESULTS

The patients were grouped according to the presence of HP or SIBO infections. Three patients were positive for both HP infection and SIBO, thus they were excluded from the study. Twenty-four patients were not infected with either HP or SIBO. Eleven patients out of 48 (22.9%; 95% CI: 12.0–37.3) were HP-infected, with a prevalence similar to the general population (20–65% of the adult population in industrialized countries) (21, 22).

The prevalence of SIBO in patients with CSU was slightly higher (27.1%; 95% CI: 15.3–41.8) than in the general asymptomatic population (0–12.5%) (23). Table I shows the main characteristics of patients evaluated at baseline: no significant differences were found between patients who were positive for HP, positive for SIBO or negative for both infections. The 3 groups were characterized by the same proportion of males, disease duration (longer than 6 months), habits (smoking), hypothyroidism, number of patients who usually took more than three drugs a day, faecal parasites, AST, PRIST levels, and age distribution. None of the patients showed hyperthyroidism.

Fig. 1 shows UAS scores evaluated at baseline, and one month after eradication, and the percentage variations between the two measurements. At baseline, patients affected by SIBO had a significantly higher UAS. After eradication patients with HP had the strongest decrease in UAS score.

Fig. 2 shows the corresponding DLQI scores. SIBO-positive patients had significantly higher scores than patients with no infection, both at baseline and after eradication. HP-positive patients had the greatest improvement in QoL: the percentage significantly decrease (median: −40) (p = 0.02).

Table I. Main patients’ characteristics evaluated at baseline according to Helicobacter pylori (HP) infection or small intestinal bacterial overgrowth (SIBO)

| Variables                  | Negative n (%) | HP n (%) | SIBO n (%) | p< 
|---------------------------|----------------|----------|------------|------
| Patients                  | 24 (50)        | 11 (22.9)| 13 (27.1)  | 0.307
| Male                      | 11 (45.8)      | 2 (18.2) | 4 (30.8)   | 0.307
| Disease duration > 6 months| 22 (91.7)      | 9 (81.8) | 10 (76.9)  | 0.486
| Smokers                   | 7 (29.2)       | 4 (36.4) | 8 (61.5)   | 0.171
| Hypothyroidism            | 13 (54.2)      | 4 (36.4) | 9 (69.2)   | 0.284
| Drugs (> 3)               | 7 (29.2)       | 2 (18.2) | 6 (46.2)   | 0.364
| Faecal parasites          | 2 (8.3)        | 2 (18.2) | 1 (7.7)    | 0.693
| Prick positive            | 2 (8.3)        | 1 (9.1)  | 1 (7.7)    | 0.686
| AST-positive              | 6 (25)         | 2 (18.2) | 2 (15.4)   | 0.898
| PRIST-positive            | 5 (20.8)       | 1 (9.1)  | 3 (23.1)   | 0.71
| ASS-positive              | 2 (8.3)        | 0 (0)    | 2 (15.4)   | 0.548

Fisher exact test.

AST: anti-streptolysin titre; PRIST: paper radioimmunosorbent test; ASST: autologous serum skin test.
DISCUSSION

The pathogenetic role of HP infection in CSU is still under discussion and no data have been reported about a possible clinical association between SIBO and CSU.

HP infection is common among the general population, but only some of the infected patients show CSU, and patients with CSU are not necessarily infected by HP.

Although some authors report a lack of association between HP eradication and remission of CSU (24, 25), other authors describe a beneficial role of HP eradication therapy on CSU (26–29).

Indeed, there are some reports of patients in CSU remission after every HP eradication (30). Differences in population characteristics (i.e. age, ethnic or geographical origin), criteria for diagnosis of HP infection, or breath testing methodology (substrate, instrument, gas or gases analysed and criteria to establish test positivity), may explain, at least in part, the differences among the studies (25).

The prevalence of HP infection in patients with CSU was similar to that reported for the general population of industrialized countries (21, 22) and the clinical severity of CSU in HP-infected patients was similar to that of uninfected patients.

HP infection was successfully eradicated in all treated patients, resulting in a significant improvement in patients’ QoL and disease severity. These data thus agree with the results of some previous studies (26, 27). However, we have to consider that the triple therapy for HP infection shows broad-spectrum activity and could eradicate other unrecognized subclinical infections related to CSU symptoms.

Our study additionally showed that the prevalence of SIBO in patients with CSU is higher (18%) than that reported for the healthy Italian population (0–12.5% values obtained from survey of the GBT). Moreover, the presence of SIBO was correlated with more serious urticarial symptoms and a worse QoL at baseline. All SIBO-positive patients were treated successfully and none showed a persistence of bacterial overgrowth after treatment. However, the eradication of SIBO was not associated with a significant improvement in urticarial symptoms.

A limitation of this study is the lack of a control group, which was not possible because the ethics committee considered the inclusion of a control group in the protocol to be unethical. For this reason further controlled studies are required to establish the role of SIBO and HP infection in inducing or worsening CSU. However, these preliminary results indicate that there is insufficient evidence to support the use of SIBO eradication therapy in CSU. On the contrary, the eradication of HP infection could result in an improvement in the severity of CSU. Remission or improvement

Fig. 1. Urticaria activity score (UAS) at baseline, after eradication (T5) and percentage variation between the 2 time-points (Kruskal-Wallis test).

Fig. 2. Dermatology Life Quality Index (DLQI) score at baseline, after eradication and percentage variation between the 2 time-points.
in urticarial symptoms after HP eradication does not necessarily indicate a causal relationship between HP and CSU, since triple therapy could also result in the eradication of other misdiagnosed subclinical infections.

The authors declare no conflicts of interest.

REFERENCES

1. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau A, et al. EAACI/GA(2) LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009; 64: 1417–1426.

2. Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau AM, et al. EAACI/GA(2) LEN/EDF/WAO guideline: management of urticaria. Allergy 2009; 64: 1427–1443.

3. Wedi B, Raap U, Wieczorek D, Kapp A. Urticaria and infections. Allergy Asthma Clin Immunol 2009; 5: 10.

4. Wedi B, Wagner S, Werfel T, Manns MP, Kapp A. Prevalence of helicobacter pylori-associated gastritis in chronic urticaria. Int Arch Allergy Immunol 1998; 116: 288–294.

5. Reddymasu SC, Sostarich S, McCallum RW. Small intestinal bacterial overgrowth in irritable bowel syndrome: are there any predictors? BMC Gastroenterology 2010; 10: 23.

6. Parodi A, Paolino S, Greco A, Drago F, Mansi C, Parodi A, et al. Small intestinal bacterial overgrowth in rosacea: clinical effectiveness of its eradication. Clin Gastroenterol Hepatol 2008; 6: 759–764.

7. Moss R, Hsu YP, Esrig S. Performance characteristics of immunoenzymatic allergosorbent testing for total and specific immunoglobulin E. Ann Allergy 1987; 59: 185–191.

8. Sabroe RA, Grattan CE, Francis DM, Barr RM, Kobza Black A, Greaves MV. The autologous serum skin test: a screening test for autoantibodies in chronic idiopathic urticaria. Br J Dermatol 1999; 140: 446–452.

9. Rueff F, Bergmann KC, Brockow K, Fuchs T, Grübl A, Jung K, et al. Skin tests for diagnostics of allergic immediate-type reactions. Pneumologie 2011; 65: 484–495.

10. Savarino V, Vigneri S, Celle G. The 13C urea breath test in the diagnosis of Helicobacter pylori infection. GUT 1999; 45: 118–122.

11. Redéén S, Petersson E, Törnkrantz E, Levander H, Mårdh E, Borch K. Reliability of diagnostic tests for helicobacter pylori infection. Gastroenterol Res Pract 2011; 2011: 940650.

12. Gasbarrini A, Corazza GR, Gasbarrini G, Montalto M, Di Stefano M, Basilisco G, et al. Methodology and indications of H2-breath testing in gastrointestinal disease: the Rome Consensus Conference. Alim Pharmacol Ther 2009; 29: 1–49.

13. Bures J, Cyran J, Kahoutova D, Förstl M, Rejchrt S, Kvetina J, et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010; 16: 2978–2990.

14. Mlynek A, Zalewska-Januwska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy 2008; 63: 777–780.

15. Mathias SD, Dreskin SC, Kaplan A, Saini SS, Spector S, Rosén KE. Development of a daily diary for patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2010; 105: 142–148.

16. Finlay AY, Khan GK. Dermatology life quality index (DLQI) – a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210–216.

17. Grob JJ, Auquier P, Dreyfus I, Ortonne JP. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. J Eur Acad Dermatol Venereol 2008; 22: 87–93.

18. Shikiar R, Harding G, Leahy M, Lennox RD. Minimal important difference (MID) of the Dermatology Life Quality Index (DLQI): results from patients with chronic idiopathic urticaria. Health Qual Life Outcomes 2005; 20: 33–36.

19. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808–1825.

20. Bures J, Cyran J, Kohoutova D, Förstl M, Rejchrt S, Kvetina J, Vorisek V, Kopacova M. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol 2010; 16: 2978–2990.

21. Jais M, Baruna S. Seroprevalence of anti Helicobacter pylori IgG/IgA in asymptomatic population from Delhi. J Commun Dis 2004; 36: 132–135.

22. Bruce MG, Maaroos HI. Epidemiology of Helicobacter pylori infection. Helicobacter 2008; 13 Suppl 1: 1–6.

23. Quingley EM, Abu-Shanab A. Small intestinal bacterial overgrowth. Infect Dis Clin North Am 2010; 24: 943–959.

24. Shakouri A, Compalati E, Lang DM, Khan DA. Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system. Curr Opin Allergy Clin Immunol 2010; 10: 362–369.

25. Dauden E, Alionso IJ, Diez AG. H. pylori and chronic idiopathic urticaria. Int J Dermatol 2000; 39: 446–452.

26. Wedi B, Raap U, Wieczorek D, Kapp A. Infections and chronic spontaneous urticaria. A review. Hautarzt 2010; 61: 758–764.

27. Fokuda S, Shimoyama T, Umegaki N, Mikami T, Nakano H, Munakata A. Effect of Helicobacter pylori eradication in the treatment of Japanese patients with chronic idiopathic urticaria. J Gastroenterol 2004; 39: 827–830.

28. Yadav MK, Rishi JP, Nijawan S. Chronic urticaria and Helicobacter pylori. Indian J Med Sci 2008; 62: 157–162.

29. Magen E, Mishal R, Schlesinger M, Scharf S. Eradication of HP infection equally improves chronic urticaria with positive and negative autologous serum skin test. Helicobacter 2007; 12: 567–571.

30. Zuberbier T. Urticaria. Allergy 2003; 58: 1224–1234.